Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.

How to buy Circassia Group stock | $0.34

Own Circassia Group stock in just a few minutes.

Updated

Fact checked

Circassia Group Plc is a business based in the US. Circassia Group shares (CSSPF) are listed on the OTCGREY and all prices are listed in US Dollars. Circassia Group employs 350 staff and has a market cap (total outstanding shares value) of USD$123.1 million.

How to buy shares in Circassia Group

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Circassia Group Find the stock by name or ticker symbol: CSSPF. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Circassia Group reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$0.34, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Circassia Group, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Circassia Group. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Circassia Group share price

Use our graph to track the performance of CSSPF stocks over time.

Circassia Group shares at a glance

Information last updated 2020-09-17.
Latest market closeUSD$0.34
52-week rangeUSD$0.22 - USD$0.455
50-day moving average USD$0.4125
200-day moving average USD$0.3272
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Compare trading platforms

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Available asset types Stock trade fee Option trade fee Annual fee
Vanguard
Stocks,Mutual funds,ETFs,Forex
$0
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
Stocks,Options,ETFs,Cryptocurrency
$0
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
TD Ameritrade
Stocks,Bonds,Options,Mutual funds,ETFs,Forex,Futures
$0
or $25 If it is broker-assisted
$0 + $0.65/contract,
or $25 Broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Interactive Brokers
Stocks,Bonds,Options,Mutual funds,Index funds,ETFs,Forex,Futures,Cash
$0
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
Stocks,Options,ETFs,Futures
$0
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Circassia Group stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Circassia Group price performance over time

Historical closes compared with the close of $0.34 from 2020-09-29

1 week (2020-09-24) 0.34
1 month (2020-09-01) -25.27%
3 months (2020-07-01) 30.77%
6 months (2020-04-01) 17.24%
1 year (2019-09-27) N/A
2 years (2018-09-27) -62.22%
3 years (2017-09-27) N/A
5 years (2015-09-30) -92.38%

Circassia Group financials

Gross profit TTM USD$46.2 million
Return on assets TTM -12.43%
Return on equity TTM -56.35%
Profit margin -67.57%
Book value N/A
Market capitalisation USD$123.1 million

TTM: trailing 12 months

Circassia Group share dividends

We're not expecting Circassia Group to pay a dividend over the next 12 months.

Circassia Group share price volatility

Over the last 12 months, Circassia Group's shares have ranged in value from as little as $0.22 up to $0.455. A popular way to gauge a stock's volatility is its "beta".

CSSPF.US volatility(beta: 1.45)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (OTCGREY average) beta is 1, while Circassia Group's is 1.447. This would suggest that Circassia Group's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Circassia Group overview

Circassia Group Plc, a specialty pharmaceutical company, focuses on the development and commercialization of respiratory products. It operates through three segments: NIOX, Chronic Obstructive Pulmonary Disease (COPD), and LungFit. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; Tudorza for the treatment of COPD; and Duaklir, a fixed-dose combination of the long-acting muscarinic antagonist aclidinium bromide and long-acting beta agonist formoterol fumarate, which is administered twice-daily through the breath actuated Pressair inhaler for the maintenance treatment of COPD. It is also developing LungFit, a portable ventilator-compatible system that utilizes an electric voltage to produce precise quantities of nitric oxide from the nitrogen and oxygen in air. The company markets its products directly to specialists in the United States, the United Kingdom, China, Italy, and Germany, as well as through a network of partners internationally. Circassia Group Plc has a collaboration agreement with AstraZeneca to promote Tudorza and Duaklir for COPD treatment; and the United States and Chinese commercial rights to LungFit. The company was formerly known as Circassia Pharmaceuticals plc and changed its name to Circassia Group Plc in May 2020. Circassia Group Plc was founded in 2006 and is headquartered in Oxford, the United Kingdom.

Frequently asked questions

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site